open access
High doses of simvastatin in ACS decrease serum PDGF levels without influencing immune activation
open access
Abstract
Material and methods: We examined 44 patients with ACS randomised into two groups: Group S(+) - 22 patients with ACS who were administered high doses of simvastatin (80 mg per day) over a period of one month from a cardiac event; Group S(–) - 22 patients with ACS treated by standard doses of statins. In all patients successful percutaneous coronary interventions (PCI) were performed. Laboratory analyses were performed at the baseline on the 7th and 30th days from an ACS and involved the following: platelet-derived growth factor (PDGF), tumour necrosis factor (TNF) alpha, soluble forms of TNF receptor (sTNFR 1 and 2), Interleukin-2 (IL-2), and IL-10.
Results: During a one-month follow-up we found no difference between clinical data and the baseline levels of the assessed markers in the groups examined. There were no differences in the consecutive measurements of TNF-a, sTNFR1, sTNFR 2, IL-2, and IL-10 levels. Serum concentrations of PDGF were significantly lower on the 7th and 30th days in group S(+) (7th: 6111 ± 1834 pg/ml, p = 0.037; 30th: 5735 ± 1089 pg/ml, p = 0.016, respectively) in comparison to group S(–) (7th: 7292 ± 1952 pg/ml; 30th: 7034 ± 2008 pg/ml, respectively).
Conclusions: High doses of simvastatin administered over a period of one month following an acute coronary syndrome were associated with a significant decrease in serum PDGF levels without influence on the activation of serum immune markers.
Abstract
Material and methods: We examined 44 patients with ACS randomised into two groups: Group S(+) - 22 patients with ACS who were administered high doses of simvastatin (80 mg per day) over a period of one month from a cardiac event; Group S(–) - 22 patients with ACS treated by standard doses of statins. In all patients successful percutaneous coronary interventions (PCI) were performed. Laboratory analyses were performed at the baseline on the 7th and 30th days from an ACS and involved the following: platelet-derived growth factor (PDGF), tumour necrosis factor (TNF) alpha, soluble forms of TNF receptor (sTNFR 1 and 2), Interleukin-2 (IL-2), and IL-10.
Results: During a one-month follow-up we found no difference between clinical data and the baseline levels of the assessed markers in the groups examined. There were no differences in the consecutive measurements of TNF-a, sTNFR1, sTNFR 2, IL-2, and IL-10 levels. Serum concentrations of PDGF were significantly lower on the 7th and 30th days in group S(+) (7th: 6111 ± 1834 pg/ml, p = 0.037; 30th: 5735 ± 1089 pg/ml, p = 0.016, respectively) in comparison to group S(–) (7th: 7292 ± 1952 pg/ml; 30th: 7034 ± 2008 pg/ml, respectively).
Conclusions: High doses of simvastatin administered over a period of one month following an acute coronary syndrome were associated with a significant decrease in serum PDGF levels without influence on the activation of serum immune markers.
Keywords
platelet-derived growth hormone; cytokines; acute coronary syndrome
About this articleTitle
High doses of simvastatin in ACS decrease serum PDGF levels without influencing immune activation
Journal
Issue
Vol 13, No 4 (2006): Folia Cardiologica
Pages
326-330
Published online
2006-04-24
Page views
555
Article views/downloads
793
Bibliographic record
Folia Cardiol 2006;13(4):326-330.
Keywords
platelet-derived growth hormone
cytokines
acute coronary syndrome
Authors
Katarzyna Mizia-Stec
Zbigniew Gąsior
Barbara Zahorska-Markiewicz
Joanna Janowska
Magdalena Mizia
Piotr Pysz
Michał Holecki
Grażyna Knauer-Janicka
